Price
No data yet.
Social Signal Score
Analyst Ratings
30 analystsRevenue
$783.30M+91.89%Analyst Estimates
Consensus estimates, not results. Via Financial Modeling Prep.
Company Profile
- CEO
- Martine A. Rothblatt
- Sector
- Healthcare
- Industry
- Biotechnology
- Employees
- 1,400
- Beta
- 0.56
- Country
- US
- Piotroski score
- 6 / 9 (Middling)
- Altman Z-score
- 20.24
Financials
Revenue
$783.30M+91.9%Net Income
$333.00M+105.8%EBITDA
$375.60M+51.6%Free Cash Flow
$205.60M-6.4%EPS (diluted)
$7.27+107.7%Shares Outstanding (diluted)
45.80M-0.9%Operating Expenses
$321.50MCash & Debt
$2.66BReturn of Capital
$58.80MRevenue by Segment (annual)
$3.18BQuote
Valuation & Ratios
Returns & Efficiency
Revenue & Net Income (Annual)
| Fiscal Year | Revenue | Net Income | EPS |
|---|---|---|---|
| 2025 | $3.18B | $1.33B | $30.13 |
| 2024 | $2.88B | $1.20B | $26.44 |
| 2023 | $2.33B | $984.80M | $21.04 |
| 2022 | $1.94B | $727.30M | $15.98 |
| 2021 | $1.69B | $475.80M | $10.60 |
| 2020 | $1.48B | $514.80M | $11.65 |
| 2019 | $1.45B | $-104.50M | $-2.39 |
| 2018 | $1.63B | $589.20M | $13.54 |
| 2017 | $1.73B | $417.90M | $9.50 |
| 2016 | $1.60B | $713.70M | $16.29 |
| 2015 | $1.47B | $651.64M | $14.17 |
| 2014 | $1.29B | $340.07M | $7.06 |
| 2013 | $1.12B | $174.56M | $3.49 |
| 2012 | $916.08M | $304.44M | $5.84 |
Valuation
Project earnings forward and see what return today's price implies.
Seeded from UTHR's reported EPS growth of 13.5% a year over 13 years.
- EPS in 5 years
- $56.75
- Implied price
- $907.99
- Return from $541.70
- 10.9% a year
To earn 15.0% a year on these assumptions you'd need to buy at $451.43 — -16.7% below today's price.
How sensitive is that answer?
Annual return across nearby assumptions. If the result is only attractive in one corner, that is the finding.
| growth \ P/E | 12 | 14 | 16 | 18 | 20 |
|---|---|---|---|---|---|
| 3.5% | -4.5% | -1.6% | 1.1% | 3.5% | 5.7% |
| 8.5% | 0.1% | 3.2% | 6.0% | 8.5% | 10.8% |
| 13.5% | 4.7% | 8.0% | 10.9% | 13.5% | 15.9% |
| 18.5% | 9.3% | 12.7% | 15.8% | 18.5% | 21.1% |
| 23.5% | 13.9% | 17.5% | 20.7% | 23.5% | 26.2% |
This is arithmetic on assumptions you chose, not a forecast or a recommendation. It ignores dividends, buybacks, share issuance and debt, and it assumes a company still earning money in 5 years. Change any input and the answer changes a lot — that sensitivity is the honest result, not a flaw in the model.
Signal Score (90d)
147+194.04%Social Signal Score
Mentions (21)
- Newszacks.com·4d ago·Neutral
UTHR Prevails in LQDA's Yutrepia Patent Dispute, Stock Up Nearly 13% United Therapeutics secures a key patent ruling against Liquidia, potentially limiting Yutrepia's PH-ILD use and reducing competition for its Tyvaso products.
View source ↗ - News (RSS)zerohedge·4d ago·Neutral
…o extend decline for a second day — after BTIG downgraded the drugmaker to neutral from buy, citing a court ruling that found Liquidia infringed two claims of rival, United Therapeutics’ patent. Nu Holdings (NU) gains 5% after the company said it’s not pursuing a deal with Monzo Bank Ltd. Oracle (ORCL) is up 1.9% after the Financial Times reports that Tencent agreed to a five-year lease across the US cloud technology firm’s data centers in Southeast Asia. Rocket Lab (RKLB) gains 4% after Citi in…
View source ↗ - Newszacks.com·5d ago·Neutral
United Therapeutics (UTHR) Moves 12.6% Higher: Will This Strength Last? United Therapeutics (UTHR) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might not help the stock continue moving higher in the near term.
View source ↗ - News (RSS)economictimes·5d ago·Negative
Why is Liquidia stock plunging? Yutrepia patent case explained Liquidia shares plunged nearly 50% after a US court ruled against the company in a patent dispute with United Therapeutics, raising concerns over Yutrepia’s commercial prospects.
View source ↗ - News (RSS)investing·5d ago·Neutral
Liquidia shares crater after court rules for United Therapeutics
View source ↗ - News (RSS)seekingalpha·8d ago·Negative
United Therapeutics: The Market Sees The Erosion, Not The Refill - Buy
View source ↗ - Newsseekingalpha.com·8d ago·Negative
…ited Therapeutics is rated Buy, with a base case valuation of $535/share, despite recent revenue declines driven by competition from Liquidia's Yutrepia. Tyvaso DPI, UTHR's largest and still-growing product, is key; declines are isolated to older formulations, not the core dry powder franchise. Upcoming catalysts include FDA reviews for IPF and Ralinepag, with label expansion and new product launches potentially driving significant upside.
View source ↗ - Newsmarketbeat.com·11d ago·Neutral
United Therapeutics Maps 14 Launches, Fibrosis Growth and Xenokidney Ambitions United Therapeutics NASDAQ: UTHR outlined plans to expand its pulmonary fibrosis, pulmonary hypertension and organ-manufacturing businesses at the Bernstein Healthcare Leaders and Disruptors Conference, with management describing a pipeline of 14 prospective product launches and continued share repurchases.
View source ↗ - News (RSS)seekingalpha·12d ago·Positive
United Therapeutics Corporation (UTHR) Presents at Bernstein Insights: Healthcare Leaders and Disruptors - 3rd Annual Healthcare Forum Transcript
View source ↗ - Newsseekingalpha.com·12d ago·Positive
United Therapeutics Corporation (UTHR) Presents at Bernstein Insights: Healthcare Leaders and Disruptors - 3rd Annual Healthcare Forum Transcript United Therapeutics Corporation (UTHR) Presents at Bernstein Insights: Healthcare Leaders and Disruptors - 3rd Annual Healthcare Forum Transcript
View source ↗ - Newsseekingalpha.com·12d ago·Neutral
United Therapeutics: Strong Catalyst Flow Bodes Well For Near-Term Growth United Therapeutics has declined ~12% since my last review, reducing its market cap to ~$21.1 billion. My previous rating was "buy" based on a compelling 2026 Tyvaso franchise plus upcoming catalysts, reflecting valuation and risk considerations. UTHR's current "buy" investment thesis centers on upcoming PDUFA dates and other catalysts that could drive future growth and re-rate the stock.
View source ↗ - Newsschaeffersresearch.com·17d ago·Neutral
Biotech Options Buzz: UTHR, NMRA, EWTX Biotech stocks are dominating today's unusual options volume list, with United Therapeutics Corporation (NASDAQ: UTHR), Neumora Therapeutics Inc (NASDAQ: NMRA), and Edgewise Therapeutics Inc (NASDAQ: EWTX) all attracting outsized attention in the options pits.
View source ↗ - News (Marketaux)gurufocus.com·21d ago·Positive
United Therapeutics Corporation at Morgan Stanley Global Healthcare Conference Transcript I'm very pleased to be hosting Unite[+324 characters]
View source ↗ - Newsseekingalpha.com·21d ago·Positive
United Therapeutics Corporation (UTHR) Presents at Morgan Stanley 24th Annual Global Healthcare Conference Transcript United Therapeutics Corporation (UTHR) Presents at Morgan Stanley 24th Annual Global Healthcare Conference Transcript
View source ↗ - Newsseekingalpha.com·26d ago·Positive
United Therapeutics Corporation (UTHR) Presents at 12th Annual Cantor Fitzgerald Global Healthcare Conference Transcript United Therapeutics Corporation (UTHR) Presents at 12th Annual Cantor Fitzgerald Global Healthcare Conference Transcript
View source ↗ - Newsseekingalpha.com·27d ago·Positive
United Therapeutics Corporation (UTHR) Presents at Wells Fargo 21st Annual Healthcare Conference Transcript United Therapeutics Corporation (UTHR) Presents at Wells Fargo 21st Annual Healthcare Conference Transcript
View source ↗ - Newszacks.com·32d ago·Neutral
FDA Accepts UTHR's sNDA for Tyvaso in Idiopathic Pulmonary Fibrosis FDA accepts United Therapeutics' Tyvaso sNDA for an IPF label expansion, backed by TETON data showing improved lung function and reduced clinical worsening.
View source ↗ - News (RSS)seekingalpha·33d ago·Neutral
United Therapeutics bid to expand nebulized Tyvaso label gets FDA review
View source ↗ - News (RSS)seekingalpha·36d ago·Neutral
United Therapeutics highlights new data supporting two FDA filings
View source ↗ - Newsbusinesswire.com·39d ago·Neutral
… European Respiratory Society International Congress 2026 SILVER SPRING, Md. & RESEARCH TRIANGLE PARK, N.C--(BUSINESS WIRE)--United Therapeutics Corporation (Nasdaq: UTHR), a public benefit corporation, today announced that four oral presentations and four poster presentations will be presented across its commercial and development portfolio at the European Society of Cardiology (ESC) Congress 2026, August 28-31 in Munich, and at the European Respiratory Society (ERS) Congress 2026, September 5-…
View source ↗ - Newszacks.com·48d ago·Neutral
UTHR Completes Phase III Tyvaso Study Enrollment for Expanded Label United Therapeutics completes enrollment in its phase III study evaluating Tyvaso for an additional indication, PPF, with top-line results expected in the second half of 2027.
View source ↗
Earnings
Wed, Nov 4(in 4 weeks)
Consensus estimate $6.46 per share
Typical surprise +3.9% (median, so one quarter with a near-zero estimate can't distort it)
- Wed, Aug 5$7.27 vs $6.86beat
- Wed, May 6$5.82 vs $7.00miss
- Wed, Feb 25$7.70 vs $7.13beat
- Wed, Oct 29$7.16 vs $6.89beat
- Wed, Jul 30$6.41 vs $7.29miss
- Wed, Apr 30$6.63 vs $6.29beat
Estimates and results for UTHR via Financial Modeling Prep. Beating consensus says the company cleared the bar analysts set, not that the business grew.
Insider trading
Open-market buys and sells by UTHR officers and directors.
- Bought
- —
- Sold
- $24.3m
0 trades
88 trades
- Rothblatt Martine Asold
- Rothblatt Martine Asold
- Rothblatt Martine Asold
- Rothblatt Martine Asold
- Rothblatt Martine Asold
- Rothblatt Martine Asold
- Rothblatt Martine Asold
- Rothblatt Martine Asold
12 further Form 4 entries are share awards, option exercises or shares withheld for tax. Those are compensation, not trades, so they are excluded above. Buying is the stronger signal: an insider spends their own money for one reason. Selling has many innocent explanations — tax, diversifying, a house — so it says far less than it appears to. Via SEC filings.
Congress trades
- Lisa C. McClainhouse · MI09 · disclosed Nov 24, 2025 (25d later)Buy$1,001 - $15,000
- Lisa C. McClainhouse · MI09 · disclosed Nov 24, 2025 (24d later)Sell$1,001 - $15,000
- Lisa C. McClainhouse · MI09 · disclosed Nov 24, 2025 (25d later)Sell$1,001 - $15,000
- Lisa C. McClainhouse · MI09 · disclosed Aug 13, 2025 (63d later)Buy$1,001 - $15,000
- Michael T. McCaulhouse · TX10 · disclosed Jun 22, 2023 (41d later)Sell$15,001 - $50,000
- Michael T. McCaulhouse · TX10 · disclosed Jun 22, 2023 (41d later)Sell$100,001 - $250,000
- Michael T. McCaulhouse · TX10 · disclosed Apr 18, 2022 (48d later)Buy$1,001 - $15,000
- Michael T. McCaulhouse · TX10 · disclosed Apr 18, 2022 (48d later)Buy$15,001 - $50,000
- Michael T. McCaulhouse · TX10 · disclosed Feb 23, 2022 (26d later)Sell$15,001 - $50,000
- Michael T. McCaulhouse · TX10 · disclosed Feb 23, 2022 (26d later)Sell$1,001 - $15,000
- Donna Shalalahouse · FL27 · disclosed Apr 27, 2020 (418d later)Sell$1,001 - $15,000
Self-reported filings, amounts as brackets. Via Senate/House disclosures.